You are here

  • Home
  • Archive
  • Volume 76, Issue 8
  • A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Authors

  1. Correspondence to Dr Bente Glintborg, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; glintborg{at}dadlnet.dk
View Full Text

Citation

Glintborg B, Sørensen IJ, Loft AG On behalf of all departments of rheumatology in Denmark, et al
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Annals of the Rheumatic Diseases 2017;76:1426-1431.

Publication history

  • Received October 28, 2016
  • Revised March 21, 2017
  • Accepted March 23, 2017
  • First published May 4, 2017.
Online issue publication 
October 31, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.